Fenfluramine - Zogenix
Alternative Names: Brabafen; Fenfluramine hydrochloride - Zogenix; FINTEPLA; Fintepla; FINTEPLA® CIV; Low-dose fenfluramine; ZX-008Latest Information Update: 21 Aug 2024
At a glance
- Originator Brabant Pharma
- Developer Nippon Shinyaku; NYU Langone Medical Center; University Hospital Schleswig-Holstein; Zogenix
- Class Amines; Amphetamines; Anorectics; Antiepileptic drugs; Fluorinated hydrocarbons; Small molecules
- Mechanism of Action Serotonin receptor agonists; Serotonin release stimulants; Serotonin uptake inhibitors; Sigma-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Dravet syndrome; Lennox-Gastaut syndrome
- Phase III Early infantile epileptic encephalopathy 2
- Phase II Myoclonic epilepsies
Most Recent Events
- 02 Jul 2024 Zogenix completes the phase II FFA-MAE trial in Myoclonic epilepsies (Adjunctive treatment, In children, In infants, In adolescents) in Germany (PO) (EudraCT2018-001664-38)
- 17 Apr 2024 Registered for Lennox-Gastaut syndrome (Adjunctive treatment, In adolescents, In children, In adults) in Japan (PO)
- 13 Nov 2023 Phase-III clinical trials in Dravet syndrome (In infants) in USA (PO) (NCT06118255)